{"title":"Appendectomy before or after ulcerative colitis and the long-term outcomes.","authors":"Cong Dai, Yu-Hong Huang","doi":"10.1093/ibd/izag178","DOIUrl":"10.1093/ibd/izag178","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148874006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joëlle St-Pierre, Maxime Delisle, Yusuke Miyatani, Katherine Falloon, Kenneth Ernest-Suarez, Baldeep Pabla, Hien Huynh, Brooke Maracle, Janice Y Kung, Noa Cleveland, David T Rubin, Michael Dolinger, Kerri Novak, Oriana Damas, Gil Y Melmed, Cathy Lu, Amelia Kellar
{"title":"Ultrasound criteria for transmural healing and response in Crohn's disease: a systematic review of definitions and thresholds.","authors":"Joëlle St-Pierre, Maxime Delisle, Yusuke Miyatani, Katherine Falloon, Kenneth Ernest-Suarez, Baldeep Pabla, Hien Huynh, Brooke Maracle, Janice Y Kung, Noa Cleveland, David T Rubin, Michael Dolinger, Kerri Novak, Oriana Damas, Gil Y Melmed, Cathy Lu, Amelia Kellar","doi":"10.1093/ibd/izag052","DOIUrl":"10.1093/ibd/izag052","url":null,"abstract":"<p><strong>Background: </strong>Transmural healing (TMH) indicates resolution of inflammation in all bowel wall layers and is an emerging therapeutic target in Crohn's disease (CD). Standardized sonographic criteria for TMH and early improvement, termed Transmural Response (TMR), have not been established. This systematic review synthesizes published definitions to provide an up-to-date overview of the current evidence base for intestinal ultrasound (IUS)-based assessment in CD.</p><p><strong>Methods: </strong>This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Comprehensive searches of databases identified full-text articles that pre-specified TMH, TMR or normal/abnormal bowel on trans-abdominal IUS in pediatric or adult participants with CD. Definitions were summarized descriptively.</p><p><strong>Results: </strong>Eighty-three full-text studies (8033 patients) met eligibility criteria; 39 (47%) defined TMH and 22 (27%) defined TMR. TMH definitions most often included bowel-wall thickness (BWT) ≤ 3mm (31/39, 79%), absent or minimal Doppler flow (25/39, 64%), and preserved bowel wall stratification (10/39, 26%). All TMR definitions required BWT reduction, but thresholds varied (absolute ≥ 1 mm or relative ≥ 25% in 16/22, 73%). Nine studies (9/22, 41%) also required Doppler flow improvement and 4/22 (18%) included additional criteria. Pediatric-specific criteria were reported in 2 TMH and one TMR studies, extrapolating from adult BWT values. Heterogeneity precluded quantitative pooling.</p><p><strong>Conclusions: </strong>Standardized IUS definitions of TMH and TMR in CD are lacking. Consistent, validated criteria are essential to enable reproducible ultrasound endpoints, support treat-to-target strategies, and facilitate incorporation of IUS into CD clinical trials and routine care.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1707-1721"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148137973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jayne Doherty, Ciaran Hurley, Parker Girod, John Peacock, Laura Neilan, Helen Muldowney, Annemarie Burke, Lorraine Stallard, Shoana Quinn, Annemarie Broderick, Emily Stenke, Seamus Hussey, Karen Hartery, David Kevans, Sarah O Donnell, Eoin Slattery, Garret Cullen, Roisin Stack, Glen Doherty, Clodagh Murphy, Billy Bourke, Cara Dunne
{"title":"Transitioning to adult care for patients with IBD: the impact of a structured IBD transition program on service engagement.","authors":"Jayne Doherty, Ciaran Hurley, Parker Girod, John Peacock, Laura Neilan, Helen Muldowney, Annemarie Burke, Lorraine Stallard, Shoana Quinn, Annemarie Broderick, Emily Stenke, Seamus Hussey, Karen Hartery, David Kevans, Sarah O Donnell, Eoin Slattery, Garret Cullen, Roisin Stack, Glen Doherty, Clodagh Murphy, Billy Bourke, Cara Dunne","doi":"10.1093/ibd/izag056","DOIUrl":"10.1093/ibd/izag056","url":null,"abstract":"<p><strong>Background and aims: </strong>The British Society of Gastroenterology recommend use of structured transition programs to improve control of chronic gastrointestinal disease in adolescents. We sought to determine the impact of attending a structured transition program on engagement of patients with inflammatory bowel disease (IBD) services and disease outcomes.</p><p><strong>Methods: </strong>We performed a retrospective multicenter study of patients with IBD prior to and post-transfer to adult services. Patients were grouped into those who attended a structured transition program and those who received standard care, transferred with a referral letter.</p><p><strong>Results: </strong>A total of 282 patients were included: 155 patients in our structured transition program cohort and 127 patients in the standard care cohort. Patients who took part in a structured transition program had significantly better engagement with adult IBD services with significantly lower rates of nonattendance at outpatient clinics 1-year post-transfer (12.3% vs 27.2%, P = .002) and significantly lower rates of disengagement with services (4.2% vs 13.1%, P = .015). There were no significant differences seen in rates of biologic failure, need for steroid/surgery or median fecal calprotectin levels between either group. Attending a structured transition program was the only factor that positively impacted engagement with IBD services in a multivariate analysis (OR 4.08, confidence interval 1.41-11.91, P = .01).</p><p><strong>Conclusion: </strong>Structured transition programs in IBD can improve engagement of patients with IBD services with significantly lower rates of disengagement with IBD services seen in our study. Large prospective studies are needed in this field to further investigate this and the impact of these programs on disease outcomes.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1731-1740"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147672790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comments on incidence estimates and rural ascertainment in the Kinta Valley IBD follow-up study.","authors":"Xiaohe Zhang, Chaochi Yue","doi":"10.1093/ibd/izag158","DOIUrl":"10.1093/ibd/izag158","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1862-1863"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148619768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinicopathological features and cancer-specific survival in young patients with ulcerative colitis-associated colorectal neoplasia: a nationwide cohort study in Japan.","authors":"Takahide Shinagawa, Koichi Komatsu, Motoi Uchino, Hiroki Ikeuchi, Kohei Shigeta, Shiro Oka, Daijiro Higashi, Shimpei Ogawa, Kazuhiro Watanabe, Masatsune Shibutani, Yoshiki Okita, Toshifumi Wakai, Yusuke Mizuuchi, Kinya Okamoto, Kazutaka Yamada, Yu Sato, Takayuki Ogino, Hideaki Kimura, Kenichi Takahashi, Koya Hida, Yusuke Kinugasa, Fumio Ishida, Junji Okuda, Koji Daito, Takayuki Yamamoto, Seiichiro Yamamoto, Fumikazu Koyama, Junichiro Hiro, Koji Komori, Dai Shida, Junya Arakaki, Fumihiko Fujita, Takatoshi Matsuyama, Hideki Ueno, Hiroki Ochiai, Atsuo Maemoto, Riichiro Nezu, Shin Sasaki, Eiji Sunami, Tatsuki Noguchi, Kenichi Sugihara, Yoichi Ajioka, Soichiro Ishihara","doi":"10.1093/ibd/izag069","DOIUrl":"10.1093/ibd/izag069","url":null,"abstract":"<p><strong>Background: </strong>The incidence of ulcerative colitis-associated colorectal neoplasia (UCAN) is increasing, but clinicopathological features and outcomes in young patients remain unclear. We aimed to clarify the characteristics and survival of UCAN diagnosed before the age of 40 using years in a nationwide Japanese cohort study conducted by the Japanese Society for Cancer of the Colon and Rectum.</p><p><strong>Methods: </strong>We retrospectively analyzed 1212 patients with UCAN treated at 43 institutions in Japan during the period from 1983 to 2020. Patients were categorized as young (<40 years) or non-young (≥40 years). Clinicopathological features, cancer-specific survival (CSS), relapse-free survival (RFS), and survival after recurrence (SAR) were compared.</p><p><strong>Results: </strong>Young-onset UCAN accounted for 252 patients (20.8%) and showed a shorter interval from UC onset to carcinogenesis (14.0 vs 17.0 years; P < .001), more frequent pancolitis (81.3% vs 74.8%; P = .012), and a higher proportion of poorly differentiated, mucinous, or signet-ring cell carcinoma (20.2% vs 13.3%; P < .001). Five-year CSS was significantly lower in young patients (85.1% vs 89.8%; P = .039), whereas RFS was comparable (86.2% vs 86.3%; P = .750). Minimally invasive surgery (MIS) was independently associated with improved CSS (hazard ratio [HR], 0.593; 95% CI, 0.356-0.987; P = .045). The SAR remained poor in both age groups (23.6% vs 28.5%; P = .468).</p><p><strong>Conclusions: </strong>When diagnosed in patients aged <40 years, UCAN is characterized by earlier carcinogenesis, extensive disease, and aggressive histology, with worse CSS. The potential role of MIS in improving prognosis warrants further prospective investigation, while the outcome of SAR remains poor irrespective of patient age.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1750-1759"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147971913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michael Doulberis, Stergios A Polyzos, Abbas Yadegar, Jannis Kountouras
{"title":"Trained immunity: An unexplored component of IBD pathogenesis.","authors":"Michael Doulberis, Stergios A Polyzos, Abbas Yadegar, Jannis Kountouras","doi":"10.1093/ibd/izag119","DOIUrl":"10.1093/ibd/izag119","url":null,"abstract":"<p><p>Trained immunity (TI) describes the capability of the innate immune system and its tissue-resident cells to acquire long-lasting functional adaptations following an initial inflammatory or microbial insult. These changes are maintained through coordinated immunometabolic rewiring and epigenetic remodeling, resulting in amplified or altered responses upon subsequent challenges. Inflammatory bowel disease (IBD) is a chronic, relapsing disorder of the gastrointestinal tract, and TI offers a useful framework for understanding disease persistence, relapse proneness, and incomplete resolution despite effective targeting of adaptive immune pathways. While TI has been extensively studies in various chronic inflammatory disorders, its role in IBD remains rather underexplored and largely confined to early preclinical evidence. Within this narrative review, we aim to address this gap by providing current insights into the potential pathogenetic mechanisms underpinning TI in IBD. We examine how the shaping of the behavior of monocytes, macrophages, and their bone marrow progenitors and how steady exposure to microbial ligands, dysbiotic metabolites, and metabolic stressors within the intestinal lumen may establish a sustained proinflammatory \"memory\" in the context of IBD. From a translational perspective, we consider how TI may favor relapse even during clinical remission and discuss its potential relevance for patient stratification, biomarker identification, and the development of novel therapeutic strategies. Ultimately, integration of TI into IBD pathophysiology may corroborate more lasting, mechanism-based approaches to remission.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1833-1842"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148470293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mustafa Mohamedrashed, Saiumaeswar Yogakanthi, Ayushi Chauhan, Sarah Lucas, Aaron Robinson, Mayur Garg
{"title":"Skin-deep connections: likelihood of skin-scarring history in patients with stricturing/penetrating Crohn disease compared with patients with nonstricturing/nonpenetrating disease and non-inflammatory bowel disease controls.","authors":"Mustafa Mohamedrashed, Saiumaeswar Yogakanthi, Ayushi Chauhan, Sarah Lucas, Aaron Robinson, Mayur Garg","doi":"10.1093/ibd/izag058","DOIUrl":"10.1093/ibd/izag058","url":null,"abstract":"<p><p>Patients with stricturing/penetrating Crohn disease had significantly more hypertrophic/keloid scars than those with nonstricturing disease in this cross-sectional proof-of-concept study, suggesting potential shared fibrotic mechanisms between cutaneous and intestinal fibrosis. If corroborated in larger and more longitudinal cohorts, overcoming potential confounders such as postsurgical scars, this novel association may help identify patients at risk and facilitate development of targeted antifibrotic therapies.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1843-1848"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147672831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Trained immunity: Breaking a dogma and a missing opportunity in IBD?","authors":"Claudio Fiocchi, Dimitrios Iliopoulos","doi":"10.1093/ibd/izag115","DOIUrl":"10.1093/ibd/izag115","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1854-1856"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148345065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Casey R Johnson, Lily Gillette, Qurbonali Qurbonov, Abigail Plone, Stefanie S Schmieder, Michael Anderson, Katie Cibelli, Yanjia Jason Zhang, Krishnan Raghunathan, Michael Field, Alka Goyal, Stacy A Kahn, Scott B Snapper, Jocelyn A Silvester, Jay R Thiagarajah
{"title":"Novel SLC10A2 variants induce primary bile acid malabsorption and dysbiosis with IBD-like features.","authors":"Casey R Johnson, Lily Gillette, Qurbonali Qurbonov, Abigail Plone, Stefanie S Schmieder, Michael Anderson, Katie Cibelli, Yanjia Jason Zhang, Krishnan Raghunathan, Michael Field, Alka Goyal, Stacy A Kahn, Scott B Snapper, Jocelyn A Silvester, Jay R Thiagarajah","doi":"10.1093/ibd/izag137","DOIUrl":"10.1093/ibd/izag137","url":null,"abstract":"<p><p>We describe biochemically and functionally validated primary bile acid malabsorption caused by novel biallelic SLC10A2 variants in a child initially diagnosed with Crohn's disease. Pediatric IBD cohort reanalysis identified PBAM-compatible genotypes, supporting selective testing when clinical features are suggestive.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1849-1853"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148420848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mohammed Nabil Quraishi, Maryam A Alahmad, Thaer Khaleel Swaid, Antonio Facciorusso, Alyssa A Grimshaw, Badr Al-Bawardy
{"title":"Incidence of acne in patients with inflammatory bowel disease treated with Janus kinase inhibitors: a systematic review and meta-analysis.","authors":"Mohammed Nabil Quraishi, Maryam A Alahmad, Thaer Khaleel Swaid, Antonio Facciorusso, Alyssa A Grimshaw, Badr Al-Bawardy","doi":"10.1093/ibd/izag032","DOIUrl":"10.1093/ibd/izag032","url":null,"abstract":"<p><strong>Background: </strong>Janus kinase (JAK) inhibitors are effective oral therapies for inflammatory bowel disease (IBD). While acne is a known adverse event in dermatological cohorts, its incidence and risk factors in the IBD population are not well-defined. We aimed to determine the pooled incidence of acne in IBD patients treated with JAK inhibitors and to explore this risk across key clinical subgroups.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis following PRISMA guidelines. MEDLINE, EMBASE, and CENTRAL were searched from inception to September 2025 for randomized controlled trials (RCTs) and observational studies reporting acne incidence in IBD patients on JAK inhibitors. Data were pooled using a random-effects generalized linear mixed-effects model. Pre-specified subgroup analyses were performed.</p><p><strong>Results: </strong>A total of 50 studies (5 RCTs, 45 observational) involving 9902 IBD patients were included. The overall pooled incidence of acne was 8.6% (95% CI: 6.4%-11.6%). Acne rates were significantly higher (P < .0001) with the upadacitinib (12.2%), compared to tofacitinib (2.6%) and filgotinib (2.3%). A numerically higher incidence was observed during induction (8.6%) versus maintenance (4.2%) therapy, though this difference was not statistically significant (P = .07). The incidence was significantly higher in the pediatric population (12.2%) compared to adults (7.4%) (P = .03). In RCTs, JAK inhibitors were associated with significantly increased odds of acne compared to placebo (OR 2.43, 95% CI: 1.33-4.43, P = .019). No statistically significant difference was observed by IBD subtype.</p><p><strong>Conclusion: </strong>Acne is a common adverse event in IBD patients treated with JAK inhibitors. The reported incidence of acne was significantly higher with upadacitinib, in the pediatric population, and numerically higher during the induction phase of treatment.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1800-1814"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}